StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences total assets

Total assets on the balance sheet at the end of each period.

Evofem Biosciences's total assets was $7.52M at Jun 30, 2026. For fiscal 2025 it was $20.27M, down 14.8% from the year before. Over ten years it grew -6.6% a year on average. The highest annual figure on record is $109.97M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.27M-14.8%
FY2024Dec 31, 2024$23.79M+125.4%
FY2023Dec 31, 2023$10.55M-58.1%
FY2022Dec 31, 2022$25.16M-40.8%
FY2021Dec 31, 2021$42.51M-61.3%
FY2020Dec 31, 2020$109.97M+288.6%
FY2019Dec 31, 2019$28.30M+605.6%
FY2018Dec 31, 2018$4.01M+1.5%
FY2017Dec 31, 2017$3.95M-69.2%
FY2016Dec 31, 2016$12.82M-68.0%
FY2015Dec 31, 2015$40.11M-47.8%
FY2014Dec 31, 2014$76.90M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$7.52M-47.7%
Q1 FY2026Mar 31, 2026$7.44M-42.2%
Q4 FY2025Dec 31, 2025$20.27M-14.8%
Q3 FY2025Sep 30, 2025$13.81M-42.3%
Q2 FY2025Jun 30, 2025$14.38M+68.2%
Q1 FY2025Mar 31, 2025$12.88M+56.7%
Q4 FY2024Dec 31, 2024$23.79M+125.4%
Q3 FY2024Sep 30, 2024$23.94M+70.1%
Q2 FY2024Jun 30, 2024$8.55M-67.2%
Q1 FY2024Mar 31, 2024$8.22M-67.3%
Q4 FY2023Dec 31, 2023$10.55M-75.0%
Q2 FY2023Jun 30, 2023$14.07M-73.7%
Q1 FY2023Mar 31, 2023$26.03M-24.7%
Q4 FY2022Dec 31, 2022$25.16M-40.8%
Q3 FY2022Sep 30, 2022$42.28M-37.3%
Q2 FY2022Jun 30, 2022$53.47M-50.8%
Q1 FY2022Mar 31, 2022$34.57M-63.0%
Q4 FY2021Dec 31, 2021$42.51M-61.3%
Q3 FY2021Sep 30, 2021$67.43M-40.0%
Q2 FY2021Jun 30, 2021$108.75M-19.5%
Q1 FY2021Mar 31, 2021$93.46M+497.4%
Q4 FY2020Dec 31, 2020$109.97M+288.6%
Q3 FY2020Sep 30, 2020$112.33M+188.1%
Q2 FY2020Jun 30, 2020$135.06M+148.2%
Q1 FY2020Mar 31, 2020$15.65M+383.8%
Q4 FY2019Dec 31, 2019$28.30M+605.6%
Q3 FY2019Sep 30, 2019$38.99M+159.5%
Q2 FY2019Jun 30, 2019$54.42M+107.9%
Q1 FY2019Mar 31, 2019$3.23M-64.0%
Q4 FY2018Dec 31, 2018$4.01M+1.5%
Q3 FY2018Sep 30, 2018$15.03M+140.6%
Q2 FY2018Jun 30, 2018$26.17M+218.6%
Q1 FY2018Mar 31, 2018$8.99M-16.2%
Q4 FY2017Dec 31, 2017$3.95M-69.2%
Q3 FY2017Sep 30, 2017$6.25M-58.9%
Q2 FY2017Jun 30, 2017$8.21M-63.6%
Q1 FY2017Mar 31, 2017$10.73M–
Q4 FY2016Dec 31, 2016$12.82M–
Q3 FY2016Sep 30, 2016$15.21M–
Q2 FY2016Jun 30, 2016$22.58M–

More Evofem Biosciences figures

See a number that looks wrong?